Cip1/Waf1 is transcriptionally activated by the tumour suppressor p53 and previous studies have shown that p21 plays a role in tumour suppression. However, the involvement of p21 in p53-mediated tumour suppression remains to be directly demonstrated in vivo. Tumour suppression mediated by p53 can be measured by comparing tumour susceptibility in animals carrying two (wild-type mice) or three (super-p53 mice) copies of the p53 gene. We have taken advantage of this genetically defined system to measure p53-mediated cell-cycle arrest, apoptosis and tumorigenesis, in a p21 wild-type and in a p21-null context. The absence of p21 significantly impaired the enhanced p53-mediated cell-cycle arrest characteristic of super-p53 cells, but did not affect the enhanced apoptosis. Importantly, in an experimental model of fibrosarcoma induction, the absence of p21 significantly decreased the tumour suppression benefit of super-p53 mice. We conclude that cell-cycle arrest through p21 plays a significant role in mediating p53-dependent cancer protection.
The tumour suppressor p53 is one of the most crucial genes controlling tumour development. More than 50% of human tumours harbour mutant p53 and the proportion of tumours with an impaired p53 activity is even greater owing to alterations in other genes within its signalling pathway (Vousden and Prives, 2005) . Upon exposure to a large variety of cellular insults, p53 is activated and induces the transcription of its target genes, which, in turn, elicit cell-cycle arrest or apoptosis (Vousden and Lu, 2002) . These two responses, p53-induced cell-cycle arrest or p53-induced apoptosis, have the potential to contribute to the final cancer protective outcome of p53, however, the relative contribution of each of them remains to be dissected.
Ever since the original identification of p21 as a direct p53 transcriptional target capable of inducing cell-cycle arrest, this protein has been considered an important mediator of p53-dependent tumour suppression (Harper et al., 1993; el-Deiry et al., 1993; Xiong et al., 1993) . The p21 protein is part of a family of cyclin-dependent kinase inhibitors controlling progression through the cell cycle. Thus, p21-deficient cells show a defective G 1 checkpoint and do not arrest upon DNA damage and other insults (Brugarolas et al., 1995; Deng et al., 1995) . Furthermore, p21-null animals develop tumours spontaneously (Martin-Caballero et al., 2001) , present increased tumour susceptibility using chemical carcinogenesis (Philipp et al., 1999; Topley et al., 1999; Weinberg et al., 1999; Jackson et al., 2002; Jackson et al., 2003; Poole et al., 2004) , and exacerbate the tumour-prone phenotype of other mouse models (Brugarolas et al., 1998; Adnane et al., 2000; Franklin et al., 2000; Yang et al., 2001 Yang et al., , 2005 Bearss et al., 2002; Martin-Caballero et al., 2004) . In contrast to this, p21-deficiency does not accelerate tumorigenesis in the absence of p53 (De la Cueva et al., 2006) , which suggests that the role of p21 in tumour suppression is dependent on p53.
To dissect the relative contribution of p21 to p53-mediated tumour suppression, we have used a genetic approach based on our previously reported super-p53 mice (Garcia-Cao et al., 2002) . These mice carry a large genomic transgene containing an intact p53 gene that behaves as a replica of the normal wild-type gene. In this manner, super-p53 mice carry three gene doses of p53, instead of the two gene copies normal for diploid organisms. Super-p53 animals show features of an enhanced p53 response, including a cancer-resistant phenotype, thus providing an excellent opportunity to evaluate in vivo the contribution of p21 to p53-mediated tumour suppression. For this, we have generated compound super-p53/p21-null mice and we have used them to test p53-mediated cell-cycle arrest, apoptosis and cancer resistance.
Role of p21 in p53-mediated cell-cycle arrest A number of previous studies have established that ionizing radiation induces a p21-and p53-dependent G 1 cell-cycle arrest (Fotedar et al., 2004) . In agreement with this, irradiation of asynchronously growing wild-type and super-p53 mouse embryo fibroblasts (MEFs) resulted in a clear decrease in the percentage of cells in S phase, whereas p21-or p53-null cells did not decrease their S-phase fraction ( Figure 1a) . Interestingly, superp53/p21-null MEFs had an impaired cell-cycle arrest, similar to p21-or p53-null cells, thus pointing to a critical role of p21 in this response. Next, we evaluated G 1 arrest in serum-starved MEFs simultaneously restimulated with serum and irradiated. As shown in Figure 1b , a very low percentage of super-p53 cells entered S phase even in the absence of DNA damage compared to wild-type cells, indicating that an extra endogenous allele of p53 reduces the capacity of cells to resume proliferation after cell cycle withdrawal by serum deprivation. More importantly, in the presence of DNA damage, the amount of super-p53 cells that reentered the cell cycle was barely detectable, and was significantly lower than in the case of wild-type cells. This observation indicates that an extra p53 gene confers a more stringent cell-cycle arrest, both after serum deprivation and upon DNA damage. As expected, the proportion of p21-and p53-null cells in S phase was significantly higher than for wild-type cells, as both genes have been shown to be crucial for imposing DNA damage-induced cell-cycle arrest. Remarkably, super-p53/p21-null cells entered S phase as efficiently as p21-and p53-null MEFs. These results imply that super-p53 cells completely lose their enhanced cell-cycle arrest when p21 is not present. We conclude that p21 is absolutely required for p53-mediated cell-cycle arrest.
In a similar series of experiments to those described above, we performed an analysis of DNA damageinduced G 2 arrest in synchronized MEFs. Serum restimulated cells were allowed to enter into S phase, and then exposed to DNA damage. In this manner, we evaluated G 2 accumulation induced by DNA damage, a response in which p53 and p21 are known to play a modest role compared to G 1 arrest (Strathdee et al., 2001; Samuel et al., 2002) . As shown in Figure 1c , cells from all the genotypes, regardless of the status of p53 or p21, underwent a normal G 2 arrest upon DNA damage (Figure 1c) , indicating that the p53/p21 pathway plays a secondary role in G 2 arrest. Together, we conclude from these assays that super-p53 cells present an enhanced and specific p53-mediated G 1 arrest that depends on the presence of an intact p21.
Role of p21 in p53-mediated apoptosis
Next, we evaluated whether p53-dependent apoptosis was altered in super-p53 cells when combined with p21 deficiency. Several reports have suggested that p21 can protect from apoptosis by inducing cell-cycle arrest À/À cells. The initial population of cells had a robust proliferative index at the time of plating (B30% S phase, not shown), but, at the time of the analysis, this decreased (to B15% S phase) in the untreated cells owing to partial confluency. (b) Synchronous serum-starved primary MEFs of the indicated genotypes were serum re-stimulated (10% fetal bovine serum (FBS)) and simultaneously exposed (right graph) or not (left graph) to 5 Gy. At the indicated times post-irradiation cells were fixed and the proportion of cells in S phase was measured. In non-irradiated controls, super-p53 cells resumed proliferation inefficiently compared to WT MEFs, and this arrest was strictly dependent on p21. Upon irradiation, neither WT nor super-p53 MEFs were able to proliferate efficiently and, again, this was strictly dependent on p21. (c) Synchronous serum-starved primary MEFs of the indicated genotypes were serum re-stimulated (10% FBS) and 16 h poststimulation (when cells had traversed through G 1 ; see b) cells were exposed to doxorubicin (2 mg/ml, Pharmacia Italia, Nerviano, Italy) or irradiation (5 Gy). The percentage of cells at G 2 was measured 12 h later. DNA damage induces a significant arrest at G 2 in all MEFs, regardless of their genotype. Serum starvation for the assays in b and c consisted in 3 days in the complete absence of serum. Cell-cycle phases were quantified in fluorescence-activated cell sorter (FACS) profiles of propidium-iodide stained preparations using the ModFit software (Verity Software House). For the three panels, values correspond to the average and s.e.m. of two independent primary MEF preparations per genotype. Asterisks indicate that the differences were statistically significant (*, **, ***: Po0.05, Po0.01, Po0.001, respectively) with respect to the untreated cells (a and c) or with respect to the genotypes that do not carry an asterisk (b). All the data are representative of at least two assays. MEFs were cultured and prepared as previously described (Palmero and Serrano, 2001 ).
Tumour suppression through the p53/p21 pathway A Efeyan et al (Fan et al., 1997; Bissonnette and Hunting, 1998; Komarova et al., 2004) . The oncogenic stress produced by the viral oncoprotein E1a is among the most efficient and best characterized apoptotic insults for primary MEFs and it is strictly dependent on p53 (Lowe and Ruley, 1993) . We introduced the adenovirus E1a gene by retroviral transduction in MEFs of different genotypes. Wild-type cells showed a marked apoptotic response when transduced with E1a, both spontaneously (Figure 2a ) or when challenged with doxorubicin ( Figure 2b ). As anticipated, p53-deficient cells were essentially insensitive to E1a, whereas super-p53 cells were hypersensitive (Figure 2a and b) . The apoptotic response of cells with normal-or super-p53 gene dosage was not altered by the absence of p21 (Figure 2a and b) . These observations indicate that p21 is irrelevant for E1a-induced and p53-mediated apoptosis.
To further explore the relevance of p21 in p53-mediated apoptosis, we evaluated thymocyte cell death after whole-body irradiation, a process that is known to be dependent on p53 . We have previously described an enhanced apoptotic response in thymocytes of super-p53 mice when compared to wild-type mice (Garcia-Cao et al., 2002) . In agreement with our previous results, we verified an increased rate of thymocyte death in super-p53 mice, compared with wild-type mice (Figure 2c ). The absence of p21 did not affect the apoptotic response regardless of the p53 gene dose (Figure 2c) . Together, the above results argue against a relevant role of p21 in p53-mediated apoptosis.
Role of p21 in p53-mediated tumour suppression
From the above cellular assays, we conclude that p21 is a relevant mediator of p53-induced cell-cycle arrest, but it is not relevant for p53-induced apoptosis. We examined whether this selective impairment in p53-induced responses affects cancer resistance. With this aim, we induced fibrosarcomas using a well-established protocol of chemical carcinogenesis with 3-methylcholanthrene. In agreement with our previous data (GarciaCao et al., 2002) , tumour-free survival curves showed a marked delay in tumour development in super-p53 mice compared to wild-type animals (Figure 3) . Interestingly, the protective effect observed in super-p53 mice was significantly diminished, but not completely abolished, in the absence of p21 (Figure 3) . We conclude that p21 Figure 2 The effect of extra p53 on apoptosis is independent of p21. (a) Primary MEFs of the indicated genotypes were infected with a plasmid encoding the adenoviral oncoprotein E1a or the empty vector and infected cells were selected for 2-3 days and then plated (3 Á 10 5 cells in 3 cm-diameter dishes). Spontaneous apoptosis was measured in both attached and floating cells 24 h after plating. E1a-induced apoptosis was independent of p21. (b) One day after plating (see above), cells infected with E1a were treated with doxorubicin (0.05, 0.1 and 0.2 mg/ml), for 24 h, and apoptotic cells were quantified as above. (c) Mice of the indicated genotypes were whole-body irradiated with 10 Gy and, 3 h post-irradiation, thymocytes were collected and apoptotic cells were quantified. Super-p53 had a significant increase in apoptosis, but this effect was completely independent of p21. Apoptosis was quantified in FACS profiles of propidium-iodide stained preparations using the ModFit software (Verity Software House). Values correspond to the average and SEM of two independent primary MEF preparations (a and b) or two mice (c) per genotype. Asterisks indicate that the differences were statistically significant (Po0.05).
Tumour suppression through the p53/p21 pathway A Efeyan et al plays a relevant, but not essential, role in p53-mediated tumour suppression.
Concluding remarks
We have generated a genetic model, super-p53/p21-null mouse strain, which presents enhanced p53-mediated apoptosis, but severely impaired p53-mediated cell-cycle arrest. These animals allow evaluating in vivo the contribution of p53-mediated cell-cycle arrest to the final outcome of p53-mediated tumour suppression. We have found that in an experimental model of fibrosarcoma induction, p21 plays a relevant role as a mediator of p53-dependent tumour suppression. Previous studies using p21-deficient mice have shown that p21 plays a relevant role in tumour suppression, however, the dependence of this activity on p53 had not been directly tested. Here, measuring a p53-dependent tumour suppression activity in vivo, we have demonstrated that p21 is a relevant component of the p53 programme for cancer protection. 
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Tumour-free animals (%) Figure 3 The effect of extra p53 on cancer susceptibility is dependent of p21. Mice (3-5 month old) of the indicated genotypes were injected with 3-methyl-cholanthrene (1 mg, Sigma-Aldrich, St Louis, MO, USA) in sesame oil and fibrosarcoma development was monitored. Kaplan-Meier survival curves were obtained and compared using the log-rank test. Statistical differences were found for super-p53 vs wild-type mice (Po0.005), for super-p53 vs superp53/p21-null (Po0.05) and for super-p53/p21-null vs p21-null mice (Po0.001).
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